Human Glioblastoma Stem-Like Cells are More Sensitive to Allogeneic NK and T Cell-Mediated Killing Compared with Serum-Cultured Glioblastoma Cells

被引:82
作者
Avril, Tony [1 ]
Vauleon, Elodie [1 ,2 ]
Hamlat, Abderrahmane [3 ]
Saikali, Stephan [4 ]
Etcheverry, Amandine [2 ]
Delmas, Caroline [5 ]
Diabira, Sylma [3 ]
Mosser, Jean [2 ]
Quillien, Veronique [1 ,2 ]
机构
[1] Ctr Eugene Marquis, Dept Biol, F-35042 Rennes, France
[2] Univ Rennes 1, CNRS, UMR 6061, Rennes, France
[3] CHU Ponchaillou, Dept Neurochirurg, Rennes, France
[4] CHU Ponchaillou, Dept Anatomopathol, Rennes, France
[5] Inst Claudius Regaud, IMSERM, U563, Dept Oncogenese Signalisat & Innovat Therapeut, Toulouse, France
关键词
cancer stem cells; cell therapy; cytotoxic T cells; glioblastoma; NK cells; ACUTE MYELOID-LEUKEMIA; NATURAL-KILLER-CELLS; PHASE-I/II TRIAL; MALIGNANT GLIOMA; DENDRITIC CELLS; RECURRENT GLIOMA; IMMUNE-RESPONSES; INITIATING CELLS; BRAIN-TUMORS; II TRIAL;
D O I
10.1111/j.1750-3639.2011.00515.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Glioblastoma multiforme (GBM) is the most dramatic primary brain cancer with a very poor prognosis because of inevitable disease recurrence. The median overall survival is less than 1 year after diagnosis. Cancer stem cells have recently been disclosed in GBM. GBM stem-like cells (GSCs) exhibit resistance to radio/chemotherapeutic treatments and are therefore considered to play an important role in disease recurrence. GSCs are thus appealing targets for new treatments for GBM patients. In this study, we show that GBM cells with stem cell characteristics are resistant to lysis mediated by resting natural killer (NK) cells because of the expression of MHC class I molecules. However, GSCs are killed by lectin-activated NK cells. Furthermore, in experiments using the therapeutic antibody CetuximAb, we show that GSCs are sensitive to antibody-mediated cytotoxicity. We confirm the sensitivity of GSC to cytotoxicity carried out by IL2-activated NK cells and tumor-specific T cells. More importantly, we show that GSCs are more sensitive to NK and T cell-mediated lysis relatively to their corresponding serum-cultured GBM cells obtained from the same initial tumor specimen. Altogether, these results demonstrate the sensitivity of GSC to immune cell cytotoxicity and, therefore, strongly suggest that GSCs are suitable target cells for immunotherapy of GBM patients.
引用
收藏
页码:159 / 174
页数:16
相关论文
共 75 条
  • [61] Natural killer cells:: from CD3-NKp46+ to post-genomics meta-analyses
    Walzer, Thierry
    Jaeger, Sebastien
    Chaix, Julie
    Vivier, Eric
    [J]. CURRENT OPINION IN IMMUNOLOGY, 2007, 19 (03) : 365 - 372
  • [62] RETRACTED: Glioma-Associated Cancer-Initiating Cells Induce Immunosuppression (Retracted article. See vol. 21, pg. 2189, 2015)
    Wei, Jun
    Barr, Jason
    Kong, Ling-Yuan
    Wang, Yongtao
    Wu, Adam
    Sharma, Amit K.
    Gumin, Joy
    Henry, Verlene
    Colman, Howard
    Sawaya, Raymond
    Lang, Frederick F.
    Heimberger, Amy B.
    [J]. CLINICAL CANCER RESEARCH, 2010, 16 (02) : 461 - 473
  • [63] Wheeler CJ, 2010, EXPERT REV NEUROTHER, V10, P483, DOI [10.1586/ern.10.26, 10.1586/ERN.10.26]
  • [64] Cancer stem cells and metastasis: Lethal seeds - Commentary
    Wicha, Max S.
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (19) : 5606 - 5607
  • [65] Wischhusen J, 2002, CANCER RES, V62, P2592
  • [66] Wu AH, 2006, J NEURO-ONCOL, V76, P23, DOI 10.1007/s11060-005-3280-7
  • [67] Expression of MHC I and NK ligands on human CD133+ glioma cells:: possible targets of immunotherapy
    Wu, Anhua
    Wiesner, Steve
    Xiao, Jing
    Ericson, Katya
    Chen, Wei
    Hall, Walter A.
    Low, Walter C.
    Ohlfest, John R.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2007, 83 (02) : 121 - 131
  • [68] Molecular and cell biology of brain tumor stem cells: lessons from neural progenitor/stem cells
    Xie, Zhigang
    Chin, Lawrence S.
    [J]. NEUROSURGICAL FOCUS, 2008, 24 (3-4)
  • [69] Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial
    Yamanaka, R
    Abe, T
    Yajima, N
    Tsuchiya, N
    Tsuchiya, N
    Homma, J
    Kobayashi, T
    Narita, M
    Takahashi, M
    Tanaka, R
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 (07) : 1172 - 1179
  • [70] Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: Results of a clinical phase I/II trial
    Yamanaka, R
    Homma, J
    Yajima, N
    Tsuchiya, N
    Sano, M
    Kobayashi, T
    Yoshida, S
    Abe, T
    Narita, M
    Takahashi, M
    Tanaka, R
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (11) : 4160 - 4167